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INTRODUCTION
Nearly two decades have passed since the release of Women’s Health Initiative (WHI)
postmenopausal hormone therapy trial findings, yet the medical community, and general public
remain unsettled by ongoing debate over the benefits and safety of sex hormone replacement
therapy (HRT). Among the contentious issues is the elevated risk of venous thromboembolism
(VTE) and stroke observed in HRT users (1). While major guidelines rightly recommend the use
of transdermal estradiol in women with risk factors, little attention has been given to the potential
impact of the type of estrogen molecule. This review aims to highlight the importance of selecting
appropriate estrogen therapy to enhance safety.
MISINTERPRETATION OF WHI DATA COMPROMISES CARE OF
HYPOGONADAL WOMEN
Hypogonadism in women of pre-menopausal age group is more frequent than is commonly
anticipated; spontaneous or autoimmune primary ovarian insufficiency affects ∼1% of the female
population, and an estimated 5% experience early menopause prior to age 45 (2). Other important
causes of premature estrogen deficiency include congenital conditions such as Turner syndrome
and Kallmann syndrome, as well as surgical oophorectomy. For these patients, HRT is a well-
established endocrine treatment aimed to replace estrogen physiologically until at least the average
age of menopause. Untreated individuals are at substantial risk of sexual dysfunction, genitourinary
symptoms, accelerated bone loss, vasomotor symptoms, and coronary heart disease (CHD) (3).
Similarly, in the management of postmenopausal women suffering from climacteric syndrome,
estrogen is unequivocally more efficacious compared to non-estrogen-based pharmacological
treatments, and plays a crucial role in holistic menopause management particularly in those with
impaired quality of life from persistent vasomotor symptoms.
Unfortunately, many healthcare providers and patients became resistant to the use of HRT in
the aftermath of WHI. Not only are menopausal women in their 50s and those with vasomotor
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symptoms unnecessarily deprived of HRT (4), there are also
worrying signs of under-treatment among young hypogonadal
women; a recent Swedish report on women with central
hypogonadism found that at least half of the cohort failed to
receive adequate replacement during their estrogen-deficient
premenopausal years, placing them at heightened risk of
complications in the ensuing years (5).
Prior to the landmark WHI trial, several large-scale
observational studies were actually in favor of HRT’s protective
effects, as treated women were found to be at lower risk of
CHD and mortality (6). To substantiate these observations,
WHI postmenopausal hormone trials set out to investigate
HRT in women aged 50–79 years; participants randomized
to intervention arms received either conjugated equine
estrogen (CEE) 0.625mg alone (absent uterus) or with cyclical
medroxyprogesterone acetate (MPA) 2.5mg (intact uterus). Not
only did WHI unexpectedly fail to demonstrate cardiovascular
benefits, a disconcerting increase in incidence of breast cancer,
stroke and VTE in treatment arms led to the premature closure
of study after a median follow-up of 5.6 years (7).
Around the same time, the Heart and Estrogen/Progestin
Replacement Study (HERS) trial also reported neutral effect of
HRT (CEE+MPA vs. placebo) on CHD risk along with increased
VTE events (8). Since then, the “timing hypothesis” has been
widely proposed to explain the discordance in observational and
trial findings because, unlike in typical clinical settings where
most patients considered for HRT are early post-menopausal, the
average age at which WHI subjects were initiated on HRT was
63.3 years (9). Indeed, post-hoc analyses showed better outcomes
including reduction in CHD risk in subgroups of age<60 or<10
years from the time of menopause (10), with corroborative CT
evidence of lower coronary calcified-plaque burden compared to
placebo arm (11).
Aside from age factor, the type of estrogen therapy should also
be carefully considered in HRT decision-making. It is imperative
that estrogen products with the greatest safety margins be
selected. However, this is an aspect that has often been overlooked
in HRT guidance, with results of WHI/HERS often being
inappropriately applied to all estrogen formulations. As will be
elaborated further, non-physiological estrogenic compounds—by
virtue of having greater propensity in inducing prothrombogenic
state across ages—should be avoided in patients prescribed HRT.
CHOICE OF ESTROGEN FORMULATION
INFLUENCES TREATMENT RISKS AND
BENEFITS
There are three main types of estrogen formulations available for
therapeutic purposes, namely 17β-estradiol (E2), ethinylestradiol
(EE) and CEE. The former (available in oral and transdermal
formulations) is the predominant endogenous human estrogen.
To overcome its poor oral bioavailability (<10%), E2 is typically
esterified or micronized; pro-drug esters, such as estradiol
valerate and estradiol acetate, undergo hydrolysis rapidly
following absorption to release E2 into the systemic circulation,
while the microcrystalline structure of micronised estradiol
(principally as estradiol hemihydrate) facilitates accelerated
absorption by its larger compound surface area and thus
minimizing first-pass metabolism (12). Conversely, transdermal
application of E2, which has moderate skin permeability, avoids
first-pass effect, and hence generates an E2:E1 (estrone, a
metabolite of E2) profile similar to normal physiology, whereas
E1 concentrations are higher after oral E2 administration (13).
However, the weak potency of E1 does not have significant impact
on the overall estrogenic bioactivity (14).
In contrast, CEE and EE are non-physiological because of
their different molecular structure and properties. EE—a near-
universal component of combined oral contraceptives (COCs)—
is a potent synthetic E2 analog with a 17α-ethinyl substitution
that binds to estrogen receptors α and β with high affinity,
prevents the oxidation of the 17β-hydroxy group, as well as
irreversibly inhibits CYP enzymes involved in the metabolism
of steroids, resulting in a very reactive intermediate (12). CEEs
are urine derivatives from pregnant horses and is a complex
mix of numerous estrogenic compounds with varying receptor
affinity, pharmacokinetics and biologic potency, as well as other
non-estrogenic steroids with unknown effects (12). Additionally,
both EE and CEE have considerably greater hepatic stimulatory
effect, altering the synthesis of various proteins including
angiotensinogen, SHBG and coagulation factors.
Given these fundamental pharmacological differences,
biological effects are expected to be dissimilar, and hence
the adverse effects observed in older trials employing non-
physiological estrogen would not be generalisable to all
estrogen formulations. Indeed, emerging data are demonstrating
comparatively greater safety and efficacy associated with E2 use.
In a population-based, case-control study of ∼400
postmenopausal women aged 30–79 years using oral hormone
therapy, CEE use was significantly associated with increased
venous thrombosis risk (odds ratio 2.08) and a trend toward
increased myocardial infarction (MI) risk when compared
with E2 (15). Further investigations demonstrated a higher
endogenous thrombin potential-based normalized activated
protein C (APC) sensitivity ratio as one of the mechanisms for
the elevated clotting propensity observed in CEE users. This is in
line with a recent large UK observational study of general female
population aged 40–79 which found that among oral HRT,
CEE(+MPA) had the greatest risk while E2(+dydrogesterone)
had the lowest risk (16). Likewise, Danish Osteoporosis
Prevention Study showed no evidence of increased thrombotic
or stroke risk in women with recent menopause onset who
received E2(± norethisterone) replacement and followed for up
to 16 years (17). Moreover, a significant reduction in combined
end-point of mortality and hospitalisations for congestive heart
failure or MI was demonstrated.
Similarly, recent HRT intervention trials in younger women
with premature ovarian failure have reported encouraging data
with E2 therapy (Table 1). Improvement in BMD, particularly
at lumbar spine, was consistently observed across studies, with
E2 demonstrating superiority to COCs (19, 21). Furthermore,
E2 has beneficial effects on several cardiovascular and uterine
parameters, which could have far-reaching impact on long-term
cardiovascular health and possibly fertility treatment outcomes,
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TABLE 1 | Summary of hormone therapy studies in (A) young women with premature ovarian failure (recent HRT trials), and (B) transgender females (retrospective &
cross-sectional studies).
References Study design HRT regimen Subjects Key findings Remarks
(A)
Popat et al.
(18)
3-year prospective,
randomized, double-blind,
single-center,
placebo-controlled clinical
trial.
Estradiol patch 100 µg/d &
cyclical oral MPA 10 mg/d
for 12 d/mo, ± Testosterone
(T) patch 150 µg/d.
145 women with
spontaneous 46, XX primary
ovarian insufficiency vs. 70
healthy female controls.
Normalization of bone mineral
density (BMD): ↑2.45% at neck
of femur (NoF), ↑7.7% at lumbar
spine (LS).
Increase in bone formation
markers.
Transdermal T did not
provide additional benefit.
5 subjects (4 received T)
had skin irritation, redness,
hirsutism, & oily skin.
Cartwright
et al. (19)
Open-label randomized trial
comparing effects of HRT
and combined oral
contraceptive pill (COCP) on
bone density.
HRT (Estradiol 2 mg/d &
levonorgestrel 75 µg for
12d/mo) vs. COCP (EE 30
µg & levonorgestrel 150µ
for 21d/mo followed by
7-day break).
50 women with
spontaneous POI recruited,
of whom 30 elected for
estrogen therapy (HRT =
15, COCP = 15). 36
completed the trial (no
treatment 52%; HRT 60%;
COCP 80%).
HRT significantly ↑ BMD at LS at
2 years, compared to COCP,
while NoF and total hip BMD
remained stable in all treated
subjects. BMD decreased at all
sites in untreated women.
HRT is superior to COCP in
improving bone density at
LS.
No adverse cardiovascular
events reported.
University of
Edinburgh
group (20–22)
12-month open-label
randomized controlled
crossover trial, comparing
effects of physiological HRT
vs. COCP on:
Estradiol patch (100 µg/d
for week 1, 150 µg/d for
weeks 2–4) & vaginal
progesterone (200 mg/12 h
for weeks 3–4) vs. COCP
(EE 30 µg/d &
norethisterone 1.5 mg/d for
weeks 1–3 followed by 7
“pill-free” days).
34 women with primary
ovarian failure (POF)
attributed to chemotherapy
or radiotherapy, idiopathic
or surgical treatment, or
Turner syndrome.
Only 4 clearly withdrew
because of intolerance to
the treatment, which was
adverse reaction to the
patch adhesives.
O’Donnell
et al. (20)
Uterine health 17 women completed
study; data from 25
subjects were analyzed.
Significant beneficial effect on
endometrial thickness, and trend
toward greater uterine volume.
HRT could benefit women
with POF seeking infertility
treatment by improving
uterine physical
characteristics.
Crofton et al.
(21)
Skeletal health 18 women completed study. Significant improvement in LS
BMD z-scores observed in HRT
but not COCP group, & only HRT
was associated with an increase
in bone formation markers.
The positive correlation of
HRT’s beneficial effect on
LS BMD to E2 levels
underscores the importance
of ensuring treatment
adequacy.
Langrish et al.
(22)
Cardio-vascular health 18 women completed the
study.
HRT was associated with lower
mean 24-h systolic & diastolic
BP throughout the treatment
period, along with reduced
plasma angiotensin II and serum
creatinine.
Compared to COCP,
physiological HRT could
have beneficial long-term
cardiovascular health
benefits.
Torres-
Santiago
et al. (23)
12-month randomized
clinical trial to assess the
metabolic effects of oral vs.
transdermal E2.
Cyclical estradiol (oral or
transdermal) for weeks 1–3,
with doses titrated to
normal E2 range in both
groups, & MPA 10mg from
days 14–21 each month.
40 women with Turner
syndrome; 20 in each
treatment arm.
No significant difference in body
composition, lipid oxidation, and
lipid concentrations.
Oral and transdermal E2
exert similar metabolic
effects when titrated to
normal E2 range. No
adverse event reported.
(B)
Asscheman
et al. (24)
Observational cohort study Various estrogen regimens 966 Transgender females;
mean age at therapy
initiation was 31.4 ± 11.4
years; median follow-up of
18.5 years.
Current EE use was associated
with 3-fold increase in risk of
cardiovascular mortality.
No increased risk was
observed in former EE users
who had changed to other
formulations & lower doses
of E2.
Dittrich et al.
(25)
Retrospective cohort study Monthly injections of
gonadotrophin-releasing
hormone agonist, & oral
estradiol valerate 6 mg/d for
2 years.
60 transgender females,
mean age 38.3 ± 11.3
years, treated with
One venous thrombosis
occurred in a 62-year-old patient
with known homozygous
methylenetetrahydrofolate
reductase mutation (genetic
predisposition to thrombosis).
Increase in LS and NoF
BMD observed. Overall safe
and effective treatment.
(Continued)
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TABLE 1 | Continued
References Study design HRT regimen Subjects Key findings Remarks
Ott et al. (26) Retrospective cohort study Transdermal E2 (2 × 100
µg/week); + oral
cyproterone acetate &
finasteride if yet to undergo
sex reassignment surgery
(SRS).
162 transwomen, mean age
36.6 ± 10.9 years, mean
follow up period of 64.2 ±
38.0 months.
None developed VTE under
cross-sex hormone therapy.
Notably 8.0% of subjects
had thrombophilic defect
(activated protein C
resistance).
Arnold et al.
(27)
Retrospective chart review Oral estradiol therapy (4–8
mg/d & spironolactone
pre-SRS, 2–4 mg/d only
post-SRS).
676 transwomen, mean age
33.2 ± 10.8 years, treated
for a mean of 1.9 years.
1 case of VTE; incidence of 7.8
events per 10,000 person-years.
Subject was in her 20s with
severe obesity (BMI of 37
kg/m2).
Getahun et al.
(28)
Electronic medical
record-based cohort study
All types of estrogens, with
subgroup analyses of “only
estradiol or estradiol first”
(E2 group), & “only
non-estradiol or
non-estradiol first” (non-E2
group) within the estrogen
initiation cohort.
2,842 transwomen,
including 853 in estrogen
initiation cohort. Mean
follow-up of 4.0 years.
Adjusted hazard ratio (HR) for
ischaemic stroke were 25.4, 2.8,
and 1.8 in non-E2 group, E2
group, and overall cohort,
respectively.
Adjusted HR for VTE were 2.8
and 2.1 in E2 group and overall
cohort, respectively. Not
calculated for non-E2 group due
to small numbers.
Although detailed
comparison of risks
between various estrogen
formulations is not possible
from limited data, it is
notable that non-E2 group
had a 9-fold higher risk than
E2-group for ischemic
stroke.
Seal et al. (29) Controlled, retrospective
case audit
Various types of estrogen
formulations.
165 transgender women,
mean age 45.7 ± 10.0 year,
with a mean follow-up of
8.95 ± 4.87 years.
VTE occurred in 1.2%, more
frequently in those treated with
CEE vs. estradiol valerate.
Nearly 8-fold increased VTE
risk with CEE use compared
to estradiol valerate.
van Kesteren
et al. (30)
Retrospective, descriptive
study
EE 100 µg/d & cyproterone
acetate 100 mg/d; in
subjects age >40 years,
transdermal E2 was
preferred (since 1989).
816 transwomen, mean age
41, treated for 7,734
patient-years.
36 cases of VTE were attributed
to hormone therapy; all but one
were oral EE users.
The switch to transdermal
E2 in age >40 years nearly
ameliorated VTE risk.
Asscheman
et al. (31)
Retrospective medical chart
review
EE 100 µg/d and
cyproterone acetate 100
mg/d.
303 transwomen, treated
for 1,333 patient-years.
19 cases (6.3%) of VTE EE-based therapy was
associated with 45-fold
increased risk of VTE.
Higher risk was also found
in age >40 years.
Wierckx et al.
(32)
Multicentre 1-year
prospective study
Transwomen <45 years
received estradiol valerate 4
mg/d whereas those >45
years received transdermal
E2 100 µ/d. All had
cyproterone 50 mg/d.
Ghent: 47 subjects, mean
age 31.7 ± 14.8; Oslo: 6
subjects, mean age 19.3 ±
2.4.
No cardiovascular or VTE events. Low risk for adverse events
at 1-year follow-up, which is
significant considering
earlier reports of high
incidence of VTE during the
first year of cross-sex
hormone therapy.
Wierckx et al.
(33)
Cross-sectional study Various estrogen
formulations
214 transwomen on
average treatment period of
7.4 years.
5% had VTE; half occurred in the
first year of therapy; Only 2
subjects were on EE or CEE,
whilst at least 3 were using
transdermal E2 at the time of
incident.
Findings deviate from other
studies. Possibly
confounded by high
prevalence of risk factors
(smoking, immobilization,
clotting disorder).
Nota et al.
(34)
Retrospective medical
records review
EE (pre-2001) and more
natural estrogens
(post-2001).
2,517 transwomen, median
age 30 years, with a mean
follow-up duration of 9.07
years.
Standardized incidence ratios of
VTE, comparing to reference
women, were 5.52 and 3.92 in
transwomen initiated on
estrogen therapy pre-2001 and
post-2001, respectively.
The change in estrogen
prescribing practice away
from EE therapy led to a
substantial decline in
incidence of VTE.
respectively (20, 22). These studies also provided evidence for
dose titration to achieve physiological serum E2 levels (21, 23).
More importantly, both oral and transdermal E2 therapy were
safe and well-tolerated in these trials.
Despite that, the current evidence base remains
disproportionately influenced by older randomized controlled
trials which employed non-physiological estrogens, with little
regards for their differential effects. In a recent Cochrane review
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examining the risk of cardiovascular events in HRT trials,
WHI and HERS—both of which employed CEE in intervention
arms—accounted for 79%(425/540) of stroke, 88%(312/353) of
VTE, and 90%(149/166) of pulmonary embolism events (35).
That would inevitably serve to confuse clinicians with a skewed
picture of HRT-associated risks being presented. More clarity is
certainly needed.
Furthermore, most guidelines on the management of female
hypogonadism (e.g., NICE 2017) continue to list COCs as
reasonable replacement therapy—with the exception of those
for Congenital Hypogonadotropic Hypogonadism, which only
recommend E2-based HRT (36). In contrast, WHO guidance
for the treatment of male hypogonadism has long emphasized
that only native testosterone should be prescribed, rather than
synthetic androgens. Similarly, HRT prescribing practices in
transgender medicine have also evolved over the past 2–
3 decades following accumulating data of the significantly
lower risk with E2 therapy compared to EE/CEE. Another
commonality between guidance for androgen replacement
in males and E2 replacement in trans-females is that it
emphasizes the importance of monitoring serum sex hormone
with the aim of achieving physiological levels. By contrast,
guidance for both young hypogonadal women and older
post-menopausal women do not recommend biochemical
monitoring (37).
DATA FROM TRANSGENDER CLINICAL
STUDIES ON COMPARATIVE SAFETY OF
ESTROGEN PRODUCTS
For individuals receiving cross-sex hormone treatment, the
major goal is to suppress endogenous sex hormone levels and
thus reduce biological secondary sexual characteristics, and to
replace sex hormone levels consistent with those of the affirmed
sex. Importantly, there are no fundamental sex differences in
response to sex steroids, and the principles of treatment are very
similar to that of HRT in hypogonadal patients. Hence such data
are wholly applicable to cis-gender patients.
In 1989, a key publication from a major center in Netherlands
on the estrogen treatment outcomes in transwomen reported
an alarming 45-fold increase in risk of VTE with EE compared
with cisgender controls (31). This finding triggered a change
in the treatment protocol to switch patients of age >40 years
to transdermal E2 in order to lower VTE risk. Although that
led to an overall reduction in adverse events, the VTE risk
remained high at 20-fold, largely because EE was still being
used by a significant proportion of entire cohort, albeit at
lower doses (30). It was also concerning that a 3-fold increased
risk of cardiovascular mortality was found to be independently
associated with long-term users of EE, consistent with the
deleterious effects on haemostatic cascade induced by EE (24).
Similarly, CEE proved to be greatly unsafe, with an 8-fold
increased risk of VTE compared with E2 in transwomen seen in
a large transgender service in UK (29).
On the other hand, E2 demonstrates an excellent safety profile
in several transgender studies (Table 1). In a large US cohort
of ∼700 subjects on E2 4–8 mg/day for a mean duration of
1.9 years, only a single case of VTE occurred (27). Similarly,
in a German cohort of 60 subjects on a relatively high oral E2
dose of 6 mg/day, including three with underlying thrombotic
tendency, only one VTE event was observed (25). Furthermore,
in an Austrian study of 162 subjects on transdermal E2, no VTE
was observed over a median follow-up of 64.2 ± 38.0 months
despite a high prevalence of smokers (∼60%) and the presence
of confirmed thrombophilic disorder (APC resistance) in nearly
10% (26).
EE has been shown to induce APC resistance similar to
that of factor V Leiden mutation, as well as increase in plasma
protein C and a decrease in plasma protein S, in a dose-
dependent manner. Additionally, non-physiological estrogens
lead to elevated inflammatory markers such as C-reactive protein
and interleukin-6, which could contribute to the prothrombotic
milleu (38). Besides first-pass liver effect driving haemostatic
dysregulation, higher prothrombotic tendencies are present with
other modes of administration (transdermal and transvaginal)
as well, providing evidence for a direct pathway induced by the
molecular structure (39, 40).
17β-ESTRADIOL REPLACEMENT
FACILITATES TREATMENT
INDIVIDUALIZATION
Another major advantage of E2 over EE/CEE is the feasibility
for dose adjustment according to serum E2 concentration. This
is important as bioequivalence between different administrative
forms (oral tablet, gel, and patch) is not well-established and
subject to wide interindividual variation (13). Moreover, titrating
to robust physiological E2 levels has been correlated with
positive outcomes on metabolic parameters and carotid intima
media (23, 41). Normative E2 values derived from healthy
normally menstruating females would serve as a good guide to
dosing (14).
CONCLUSION
The choice of estrogen formulation is vital to ensure optimisation
of safety and treatment efficacy. Compelling data from recent
literature supports the use of E2 over EE/CEE to avoid
the excessive vascular risk that the latter formulations are
associated with. Further studies should seek to build on
available evidence and provide greater clarity on estrogen
replacement to empower clinicians and patients to make better
therapeutic decisions.
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